期刊文献+

超越pharmaceutical care,呼唤中国特色的药学实践规范 被引量:4

Discussion on Pharmaceutical Care and Calling for Good Pharmacy practice of China
下载PDF
导出
摘要 本文将各种药学实践模式及中国药学实践规范加以阐述。药学实践在美国可分为 5个阶段 ,Pharmaceuticalcare (PC)是美国药学发展的一个新阶段 ,此概念已进入国内药学。虽然国外药学已走上规范化发展 ,但国内药学存在许多问题 ,药学工作离规范化发展相距甚远 ,因而建立中国药学实践规范极有必要。为此 ,我们提出了中国药学实践规范的初步建议。 The existing pharmacy practice model is reviewed and good pharmacy practice of China is proposed. In the USA, pharmacy evolution is regarded as 5 stages, and pharmaceutical care is a new stage. Though pharmacy development abroad is undergoing a good practice model, pharmacy in China has many issues to be solved. Therefore good pharmacy practice of China is essential.
出处 《中国药事》 CAS 2001年第5期307-310,共4页 Chinese Pharmaceutical Affairs
关键词 药学实践规范 PC 药学模式 pharmaceutical care good pharmacy practice
  • 相关文献

参考文献10

  • 1魏水易 张钧.Pharmaceutical care中文译名的商榷[J].中国药学杂志,1999,34(8):566-566.
  • 2胡晋红.美国的药学服务[J].中国药房,1998,9(6):283-285.
  • 3Holland RW, Nimmo CM. Transitions, part1:Beyond pharmaceutical ca re. Am JHealth-Syst Pharm, 1999,56:1758
  • 4Khan MA, Herzog CA, Peter JV St., et al. The prevalence of cardia c valvularinsufficiency assessed by transthoracic echocardiography in obese pat ients treated withappetite-suppressant drugs. N Engl J Med, 1998, 339:713
  • 5Hirsch J. Magic bullet for obesity. BMJ, 1998,317:1136
  • 6Weissman NJ, Tighe JF, Gottdiener, et al. An assessment of heart-valveabnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramineor placebo. N Engl J Med, 1998,339:725
  • 7Jick H, Vasilakis C, Weinrauch, et al. A population-based study o fappetite-suppressant drugs and the risk of cardiac-valve-regurgitation. N Eng l J Med,1998,339:719
  • 8Editorials. Appetite suppressants and valvular heart disease. N E ngl J Med,1998,339:765
  • 9周玲,刘惠民,官吉清.“大处方”产生的原因及解决办法[J].中国药事,2000,14(1):23-24. 被引量:5
  • 10陈海松 刘维俊.1998年FDA公布的部分撤销药品名单[J].药学进展,2000,24(1):61-61.

二级参考文献2

  • 1陈文选 颜火兴.药品回扣与医疗体制改革[J].中国药房,1997,(3):101-101.
  • 2张恩娟 张昭.浅析“医药分业”[J].中国药房,1996,7(5):236-236.

共引文献76

同被引文献24

  • 1曹园.西沙必利受到严重警告[J].药学进展,1999,23(4):250-250.
  • 2Holland R W, Nimmo C M. Transitions, partl : beyond pharmaceutical care[J]. Am J Health-Syst Pharm, 1999, 56:1758 - 1764.
  • 3Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women' s Health Initiative randomized controlled trial[J]. JAMA, 2002, 288(3):321 -333.
  • 4Lacey J V Jr, Mink P J, Lubin J H, et al. Menopausal hormone replacement therapy and risk of ovarian cancer[J]. JAMA, 2002, 288(3) :334 - 341.
  • 5Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS Ⅱ)[J]. J AMA, 2002, 288(1):58-66.
  • 6Raise L G, Prestwood K M. Estrogen and the risk of fracture-new data,new questions[J]. N Engl J Med, 1998, 339(11): 767-768.
  • 7Khan M A, Herzog C A, Peter J V St, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs [ J ]. N Engl J Med,1998, 339( 11 ) :713 - 718.
  • 8Hirsch J. Magic bullet for obesity[J]. BMI. 1998.317,1136- 1138.
  • 9国家药品监督管理局执业药师资格认证中心.药学综合知识与技能[Z].,..
  • 10Reese R E.抗生素手册[M].郭仁宣,等译.沈阳:辽宁科学技术出版社,2002.

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部